Though Polycom received a revised non-binding acquisition offer from a private equity firm worth more than $1.6 billion, it reaffirmed its previous commitment to merge with Mitel Networks.
Blue Coat has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Shares of Flexion Therapeutics dropped early on Wednesday following the announcement of an underwritten public offering.
Akamai Technologies and Nortek will forfeit ill-gotten gains connected to bribes paid to Chinese officials by foreign subsidiaries.
FuelCell Energy is scheduled to release its fiscal second-quarter financial results after the markets close on Wednesday.
Shares of LDR skyrocketed in Tuesday's session following the definitive agreement for Zimmer Biomet to acquire the company for $1 billion.
Shares of Biogen slumped early in Tuesday's session following the release of less-than-favorable top-line results from its mid-stage clinical study evaluating opicinumab.
Valeant Pharmaceuticals International reported disappointing first-quarter financial results before the markets opened on Tuesday.
Lululemon Athletica is expected to report its fiscal first-quarter financial results before the markets open on Wednesday.
The U.S. Securities and Exchange Commission (SEC) recently charged two men from Rhode Island with insider trading in the securities of deal targets being pursued by the pharmaceutical company where one of them worked.…
The ASCO annual meeting is absolutely making waves in the pharmaceutical industry. As a result, analysts are giving their two cents on companies making presentations at the conference.
The SEC has charged a New York City-based trader with defrauding investors by misrepresenting her investment track record, the profitability of her investments and her use of investor funds.
Elevate Credit decided to postpone its offering back in January, but now it is back on the table. The entire offering is valued up to about $91 million.
Some call the ASCO annual meeting the "Super Bowl for biotechs" because of the significance it holds for so many companies.
At Home Group has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
The annual meeting for ASCO is generally one of the biggest weeks of the year for the health care sector. However, there are inevitably winners and losers.
As the annual meeting for the American Society of Clinical Oncology (ASCO) is underway, we are starting to see some winners shake out from it. Currently one of the biggest winners is Vascular Biogenics…
Ocular Therapeutix shares plunged early on Monday following less-than-favorable results, although the news was not all bad.
Broadcom exceeded EPS expectations for its first quarter operating as a combined company. After the report, the stock hit a new all-time high.
Ciena reported second-quarter fiscal 2016 results before markets opened Thursday. The company won out on this earnings report, and as a result analysts poured into the stock.
